All In Biotech

NDA 217159 · Ayrmid Pharma

Aphexda

Motixafortide Acetate · Subcutaneous

NovelOrphan

CDER novel approval, Sep 8, 2023: To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma

Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 8, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

1 Phase 3, 5 recruiting

FAERS reports

102

11 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 15, 2026.

APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. APHEXDA, a hematopoietic stem cell mobilizer, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. ( 1 )

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 8, 2023 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelReview
1 products under this application
  • APHEXDA · MOTIXAFORTIDE ACETATE EQ 62MG BASE/VIAL · POWDER, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Motixafortide" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injection site pain40
  • pruritus26
  • urticaria20
  • flushing16
  • rash12
  • injection site erythema11
  • paraesthesia10
  • injection site pruritus9
  • injection site reaction9
  • hypersensitivity7
  • discomfort6
  • injection site swelling6

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
20232
202466
202518
202615

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Aphexda (Motixafortide Acetate) · HCPCS J2277

2024 spending

$923K

Beneficiaries

60

69 claims

Per beneficiary

$15,390

2024 ASP limit $25.22 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$923,386

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Ayrmid Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.